AstraZeneca pauses COVID-19 vaccine trial after unexplained illness in U.K.: reports

A study testing a potential COVID-19 vaccine developed by AstraZeneca and the University of Oxford has been put on hold over a “potentially unexplained illness” in the United Kingdom, according to media reports.

Oxford University has partnered with AstraZeneca, a British-Swedish multinational pharmaceutical and biopharmaceutical company, to produce 2 billion doses of the vaccine.

Read more: Here’s when experts say Oxford University’s coronavirus vaccine could be ready

Stat News was the first to report the development.

In a statement emailed to Stat News, CNN and CNBC, a spokesperson from AstraZeneca said the company’s “standard review process triggered a pause to vaccination to allow review of safety data.”

“This is a routine action which has to happen whenever there is a potentially unexplained illness in one of the trials, while it is investigated, ensuring we maintain the integrity of the trials,” the statement reads.

Story continues below advertisement

The statement says in large trials illnesses happen “by chance,” but must be “independently reviewed to check this carefully.”

Oxford University COVID-19 vaccine trials raises ethical concerns

Oxford University COVID-19 vaccine trials raises ethical concerns

The company says it is “working to expedite the review of the single event” to “minimize any potential impact on the trial timeline.”

[ Sign up for our Health IQ newsletter for the latest coronavirus updates ]

The Oxford University vaccine is one of many being tested to determine if they are safe and effective at treating the novel coronavirus.

Read more: 9 drugmaker executives testing coronavirus vaccines pledge safety, high standards

Earlier on Tuesday, nine leading U.S. and European vaccine developers pledged to uphold scientific safety and efficacy standards for their experimental vaccines despite the urgency to contain the pandemic.

The companies, including AstraZeneca, Pfizer Inc and GlaxoSmithKline, issued what they called a “historic pledge” after a rise in concern that safety standards might slip in the face of political pressure to rush out a vaccine.

Story continues below advertisement

Fauci on his fears, a COVID-19 vaccine, Canada-U.S. border restrictions

Fauci on his fears, a COVID-19 vaccine, Canada-U.S. border restrictions

The companies said they would “uphold the integrity of the scientific process as they work towards potential global regulatory filings and approvals of the first COVID-19 vaccines.”

In a previous interview with Global News, Dr. Brian Dixon, a biology professor at the University of Waterloo and Canada Research Chair in Fish and Environmental Immunology, said third-stage trials are also when researchers determine if there are any severe side effects associated with the vaccine.

Read more: Developing coronavirus treatments ‘extremely important,’ experts say

He said these can include excessive fever causing hospitalization or disability and excessive swelling causing meningitis or Kawasaki disease.

According to Dixon, if more than one in 100,000 people have been found to experience severe side effects during a stage-three trial, the vaccine likely won’t be approved.

Story continues below advertisement

–With files from Reuters

© 2020 Global News, a division of Corus Entertainment Inc.

Read The Full Article At Global News. This content is provided by Global News at public RSS feed. Please contact us if you have any questions.

Be the first to comment

Leave a Reply

Your email address will not be published.


This site uses Akismet to reduce spam. Learn how your comment data is processed.